19 January 2023 | News
She will be a member of Asieris' executive leadership team
Asieris Pharmaceuticals, a China-based biopharma company specialising in discovering, developing and commercialising innovative drugs for the treatment of genitourinary tumors and other related diseases, has announced that Linda Wu, PhD will join Asieris as Chief Development Officer. She will be a member of Asieris' executive leadership team, with a key role in the strategy development and management of corporate's product portfolio, and the development and execution of the global clinical pipeline.
Dr Linda has over 20 years of industry experience and a successful track record in new drug R&D, commercialisation, and portfolio management, including extensive global experience in building and leading clinical R&D teams to successfully launch innovative oncology products in China and global markets.
She joins Asieris from Janssen Pharmaceuticals, a Johnson & Johnson company, where she most recently served as a Group Medical Director of Oncology, US Medical Affairs. She has tremendous experiences in drug R&D in China, serving as a Senior Director and the Head of Clinical Development of Oncology, and the Compound Development Team Leader at Janssen in China. Dr Linda led and contributed to the approvals and launches of multiple oncology assets in China, including the unprecedented conditional approval of ERLEADA for treating non-metastatic castration-resistant prostate cancer (nm-CRPC) in 2019. Prior to her roles in clinical development, she had over ten years of research and management experiences in drug discovery at Bayer Pharmaceuticals and Janssen, with expertise in small and large molecules in multiple therapeutic areas such as metabolic and autoimmune diseases.